







an Open Access Journal by MDPI

# **Current Immunotherapy Approaches against Skin Cancer**

Guest Editor:

#### Prof. Dr. Mauro Salvatore Alessandro Alaibac

Department of Dermatology, University of Padua, Padova, Italy

Deadline for manuscript submissions:

31 October 2024

## **Message from the Guest Editor**

The advent of immunotherapy has profoundly transformed the landscape of cancer management with a substantial impact on patient care, emphasizing the importance of patient-tailored approaches. This paradigmatic shift brought about by immunotherapy has deeply influenced the management of dermatologic patients, particularly in the melanoma and non-melanoma skin cancer fields, offering breakthroughs in treating advanced stages. Furthermore, ongoing trials highlight the continuous evolution of our understanding of immunotherapy's potential. The evidence supporting the efficacy of immunotherapy is still growing, emphasizing the need for continued investigation and research.

We invite colleagues around the world to report their clinical experience with immunotherapy approaches against melanoma, non-melanoma skin cancer, Merkel cell carcinoma, skin adnexal carcinomas, and soft tissue sarcomas. Clinical contributions regarding immunotherapy approaches in skin cancer management, in the format of case reports, case series, reviews, and clinical studies (retrospective and/or prospective), are welcome for this Special Issue.

Thank you for your contribution.













an Open Access Journal by MDPI

## **Editor-in-Chief**

## Prof. Dr. Edgaras Stankevičius Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania

## **Message from the Editor-in-Chief**

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Medicina* (ISSN: 1648-9144). *Medicina* is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications on medicine. The scientific community and the general public can access the content free of charge as soon as it is published.

#### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed,

MEDLINE, PMC, and other databases.

Journal Rank: CiteScore - Q2 (General Medicine)

#### **Contact Us**